Institutional Manager · CIK 0001766721
Aisling Capital Management LP
NEW YORK, NY · File #028-19070
Latest AUM
$478.9M
Positions
13
Top-10 Concentration
99.6%
Filings
9
Portfolio Value Over Time
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
Biggest QoQ Changes
Ranked by conviction flow (share change × current price) so mark-to-market moves don't dominate. Price effect column shows how much of the $ change was just the stock moving.
| Action | Issuer | Ticker / CUSIP | Δ Shares | Flow ($) | Price Effect |
|---|---|---|---|---|---|
| REDUCE | BridgeBio Pharma Inc. (BBIO) | BBIO | -1,000,000 | -$76.5M | +$149.5M |
| EXITED | Verona Pharma plc (VRNA) | 925050106 | -615,352 | -$65.7M | $0 |
| EXITED | Nuvation Bio Inc. (NUVB) | 67080N101 | -2,960,659 | -$11.0M | $0 |
| NEW | Urogen Pharma Ltd. (URGN) | URGN | +108,000 | +$2.5M | $0 |
| REDUCE | Aclaris Therapeutics Inc (ACRS) | ACRS | 0 | $0 | +$482,245 |
| REDUCE | Bicara Therapeutics Inc. (BCAX) | BCAX | 0 | $0 | +$591,676 |
| REDUCE | Biomea Fusion Inc (BMEA) | BMEA | 0 | $0 | -$1.6M |
| REDUCE | CalciMedica, Inc. (CALC) | CALC | 0 | $0 | +$1.8M |
| REDUCE | Compass Pathways Plc (CMPS) | CMPS | 0 | $0 | +$1.4M |
| REDUCE | Marker Therapeutics, Inc. (MRKR) | MRKR | 0 | $0 | +$194,376 |
Sector Allocation
Filing History
- 13F HOLDINGS REPORTQ/E Dec 202513 pos · $478.9M
- 13F HOLDINGS REPORTQ/E Sep 202514 pos · $456.4M
- 13F HOLDINGS REPORTQ/E Jun 202513 pos · $359.7M
- 13F HOLDINGS REPORTQ/E Mar 202513 pos · $288.5M
- 13F HOLDINGS REPORTQ/E Dec 202415 pos · $281.8M
- 13F HOLDINGS REPORTQ/E Sep 202416 pos · $261.1M
- 13F HOLDINGS REPORTQ/E Jun 202415 pos · $231.1M
- 13F HOLDINGS REPORTQ/E Mar 202416 pos · $295.5M
- 13F HOLDINGS REPORTQ/E Dec 202317 pos · $242.7M
Top 13 Holdings — Dec 2025
| # | Issuer | Ticker | Shares | Value | % of Portfolio |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 5,089,611 | $389.3M | 81.29% |
| 2 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,316,806 | $27.7M | 5.78% |
| 3 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 1,472,331 | $23.1M | 4.82% |
| 4 | Bicara Therapeutics Inc. (BCAX) | BCAX | 568,919 | $9.6M | 2.00% |
| 5 | Compass Pathways Plc (CMPS) | CMPS | 1,198,418 | $8.3M | 1.73% |
| 6 | BridgeBio Oncology Therapeutics (BBOT) | BBOT | 564,625 | $7.1M | 1.48% |
| 7 | CalciMedica, Inc. (CALC) | CALC | 521,114 | $3.4M | 0.72% |
| 8 | Scholar Rock Holding Corporation (SRRK) | SRRK | 77,031 | $3.4M | 0.71% |
| 9 | Biomea Fusion Inc (BMEA) | BMEA | 2,048,757 | $2.5M | 0.53% |
| 10 | Urogen Pharma Ltd. (URGN) | URGN | 108,000 | $2.5M | 0.53% |
| 11 | Aclaris Therapeutics Inc (ACRS) | ACRS | 434,455 | $1.3M | 0.27% |
| 12 | Marker Therapeutics, Inc. (MRKR) | MRKR | 325,370 | $484,801 | 0.10% |
| 13 | OnKure Therapeutics, Inc. (OKUR) | OKUR | 88,607 | $256,960 | 0.05% |